Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-700 · 1 trial · 1 indication
Evaluation of vital signs, clinical lab testing, physical exams and adverse event monitoring
Pharmacokinetic profile of ABT-700 analyzed from blood samples
| Arm | Type | Description |
|---|---|---|
| Cohort A | EXPERIMENTAL | ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700. |
| Cohort B | EXPERIMENTAL | ABT-700 plus docetaxel. |
| Cohort C | EXPERIMENTAL | ABT-700 plus FOLFIRI/cetuximab |
| Cohort D | EXPERIMENTAL | ABT-700 plus erlotinib |
| Name | Type | Description |
|---|---|---|
| ABT-700 | DRUG | ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700. |
| docetaxel | DRUG | Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles. |
| FOLFIRI | DRUG | 5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles. |
| cetuximab | DRUG | Cetuximab will be administered by intravenous infusion weekly. |
| erlotinib | DRUG | Erlotinib will be taken orally daily. |
Inclusion Criteria: * Subject with advanced solid tumors; Dose-expansion: evidence for MET gene amplification. * Subject must have disease: a) that is not amenable to surgical resection, or b) that has progressed or recurred despite standard therapy, or c) that has failed to respond to standard the...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ABT-700 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is intended for patients with advanced solid tumors, though its efficacy and safety have not been established.
ABT-700 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical research on this investigational oncology drug for advanced solid tumors.
ABT-700 is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for advanced solid tumors.
ABT-700 has one completed Phase 1 clinical trial, identified as NCT01472016, titled "Study of ABT-700 in Subjects With Advanced Solid Tumors." The trial enrolled 74 participants aged 18 years and older with advanced solid tumors. The study is no longer active.
No alternative names for ABT-700 have been disclosed. The drug is identified solely as ABT-700 in clinical trial records and is being developed by AbbVie Inc. for advanced solid tumors.